



**PRESS RELEASE**

**Proteome Sciences plc  
(the "Company" or the "Group")**

**Publication of Annual Report**

31 May, 2016: The Company announces that its Annual Report and Accounts for the year ended 31 December 2015, together with a notice of the Annual General Meeting and accompanying form of proxy, are available to view on the Company's website at [www.proteomics.com](http://www.proteomics.com), and will be posted to shareholders imminently.

**ENDS**

**For further information please contact:**

**Proteome Sciences plc**

Christopher Pearce, Executive Chairman  
Dr. Ian Pike, Chief Operating Officer  
Geoff Ellis, Finance Director

Tel: +44 (0)1932 865065

**finnCap Limited (Nominated Adviser/Broker)**

Geoff Nash/James Thompson

Tel : +44 (0)20 7220 0563

**Public Relations**

**IKON Associates**

Adrian Shaw

Email: [adrian@ikonassociates.com](mailto:adrian@ikonassociates.com)

Tel: +44 (0)1483 271291

Mobile +44(0)7979 900733

## Notes for editors:

### About Proteome Sciences plc ([www.proteomics.com](http://www.proteomics.com))

With its HQ in Cobham, UK and laboratory facilities in London and Frankfurt, Proteome Sciences is a global leader in applied proteomics offering high sensitivity, proprietary technologies and workflows in cell signalling pathways (SysQuant<sup>®</sup>, TMTcalibrator<sup>™</sup>) and in protein biomarker discovery, validation and assay development.

PS Biomarker Services<sup>®</sup> provides proteomics outsourcing services and proprietary biomarker assays from its ISO 9001: 2008 facility in Frankfurt, Germany to pharmaceutical, biotechnology, diagnostics companies and academia.

Proteome Sciences' research has discovered a large number of novel protein biomarkers in key human diseases with a focus mainly in neurological/neurodegenerative conditions and in cancer. It has patented blood biomarkers in Alzheimer's disease, stroke, brain damage and cancers for diagnostic and treatment applications that are available for licenses.